Novartis India’s Post

Just re-read this inspiring piece on Forbes India featuring Vas Narasimhan, CEO of Novartis, that amplified my sense of pride and affirmation in the path-breaking work we're accomplishing here in India. Novartis is not just operating in India, but also supporting the innovation and development of pharma for the world from India, a testament to the immense talent and potential of our country.   My personal motivation and belief in the work we do has always been strong, and seeing Vas articulate this vision, of harnessing the power of Indian talent to drive global innovation, resonates deeply with me. The sense of commitment to India, its society, and its people is indeed heartening and reinforces my respect for the organization. We are showcasing to the world that India is a hub of innovative medicine, an illustration that Indian contributions are valued and integral to the global mission. It serves as a significant reminder that we are part of a bigger cause, contributing to the global health in dynamic and transformative ways.   Check out this insightful article to learn more about the focus Novartis is creating in India and how it is reimagining medicine for the world.    Novartis India #WeAreNovartis #NovartisIndia #ProudIndian #Innovation #GlobalImpact #ReimaginingMedicine

Recently, India made a significant move to streamline access to critical medications by waiving local trials for drugs already approved in the US, UK, EU, Australia, and Japan. This bold decision could revolutionize healthcare in India by expediting access to vital treatments for rare diseases and advanced cancers. This regulatory change isn't just about speeding up processes; it's about prioritizing patient needs and ensuring life-saving drugs reach those who need them most. While this approach promises quicker access, maintaining safety and efficacy remains paramount. As a professional in the healthcare industry, I see this as an opportunity to foster global collaboration and innovation. By aligning with international standards, India can enhance its healthcare landscape and set an example for others. How do you think this decision will impact the future of healthcare in India and beyond? Let's discuss the potential benefits and challenges. #HealthcareReform #PatientAccess #GlobalHealth #PharmaceuticalInnovation Source: (https://lnkd.in/gcAKvsBn)

🌐 Exciting discussions at the III International Pharmaceutical Forum "Global Pharm"! 🏥 One of the engaging sessions that caught our attention was the panel discussion on "Value-Oriented Approach – Managing Healthcare Systems Based on Results". Vyacheslav Dudnik, the Deputy Minister of Healthcare of Kazakhstan, shared valuable insights into why Value-Based Healthcare (VBH) is essential. He highlighted that the current healthcare payment system primarily considers the volume of medical services, and there's a pressing need to shift towards a system that focuses on patient outcomes. What is Value-Based Healthcare (VBH)? Value-Based Healthcare (VBH) is a patient-centered approach that prioritizes the quality and effectiveness of healthcare services over sheer quantity. It ensures that healthcare providers are incentivized to deliver high-quality care that leads to improved patient health and satisfaction. VBH aligns healthcare incentives with the best interests of patients. Why is VBH Important? 1. Enhanced Patient Outcomes: VBH encourages healthcare providers to concentrate on what matters most – the well-being of the patient. It drives improvements in care quality, resulting in better health outcomes and higher patient satisfaction. 2. Efficiency: By emphasizing value over volume, VBH reduces unnecessary procedures and treatments, resulting in cost savings for healthcare systems and patients. 3. Transparency: VBH relies on transparent data and outcomes measurement, fostering accountability and driving continuous improvement in healthcare delivery. 4. Patient-Centered Care: VBH empowers patients to make informed choices about their healthcare and actively participate in their treatment decisions.   The panel discussion also featured insightful presentations by prominent speakers: - Claudia Ricardo, Market Access & External Affairs Director, Roche Portugal - Lauma Valtere, Managing Director Kazakhstan, CCL Pharmaceutical (CIS countries, except Russia) at Bayer - Toylan Senel, General Manager Roche Kazakhstan, Head Roche Central Asia - Altynshash Dzhaksybayeva, Chief Pediatric Neurologist of the Ministry of Health of the Republic of Kazakhstan, MD, Head of the Department of Neurology, Medical University Astana - Alexey Scherbinsky, Head of the Main Department of Medical Care Organization of the Ministry of Health of the Republic of Belarus 🚀 These discussions are a significant step towards a more patient-centered and results-driven healthcare system. Together, we can make a positive impact on healthcare delivery in the region. #GlobalPharm #Healthcare #VBH #ResultsDrivenHealthcare 🏆  

Pharmaceutical companies often attribute high medicine prices to R&D costs. But Cipla shatters this myth. Founded in 1935 by Dr. Khwaja Abdul Hamied, Cipla aimed to make healthcare accessible to all. Dr. Hamied’s vision was clear: affordable healthcare. As the years passed, the torch was handed over to his son, Yusuf Hamied, who continues to build on this legacy. Cipla grew into a pharmaceutical titan. Could Cipla revolutionize healthcare with affordable treatments? Their crowning achievement: Triomune. This life-saving HIV/AIDS medication brought hope to millions at a fraction of international prices. Today, nearly 90 years later, Cipla is a global force with a presence in over 80 countries and an impressive portfolio of more than 1,500 offerings. This reflects the power of the family’s vision to transcend boundaries. Cipla’s story isn’t just about innovation. It’s about staying true to its roots. At its core, it remains a family-managed business, guided by the same principles of care and quality that have been its hallmark for nearly 9 decades. From humble beginnings to global impact, Cipla’s journey proves that transformative change is possible without losing sight of purpose. As you reflect on the role of legacy and purpose in driving a business forward, what legacy do you aspire to leave? #familyoffice #familybusiness #entrepreneurship #vision #fmb Photo credit: Cipla Archives

Our year at Novartis is off to a great start!   Our focus and ambition to improve human health is our daily driving force, and we look forward throughout the year to our quarterly earning markers.   Our earnings results are more than numbers. They reflect people who have benefited from our medicines. They show the promise of our pipeline. They show our continued commitment and investment in unlocking science to find the next breakthrough.   It’s a privilege to be in an industry that strives to better humanity, and it also comes with tremendous responsibility. We never forget this at Novartis. Like the trees, we must continuously grow, reach high to fuel innovation, and stand together in shared purpose. We know that by reimagining medicine, together, a healthier future for all is in reach!   Read more about our Q12024 earnings: ttps://https://lnkd.in/eyxhhPbu   #reimaginingmedicinetogether

Over the past decade, Taj Pharmaceuticals Group has been diligently shaping a new paradigm in healthcare. Throughout our organization in India, we nurture enduring relationships founded on mutual confidence. This commitment is evident in our actions – our scientists earn trust through groundbreaking discoveries, our sales and marketing teams work tirelessly to improve global health, and our colleagues at every level strive to be trustworthy. This journey demands relentless effort, impeccable execution, unwavering integrity, and transparency from all Taj Pharmaceuticals Group members. Our global team remains resolute in expanding innovative treatments and increasing access to quality healthcare worldwide. We aspire to excellence in three core areas: our people, our products, and our processes. The fruits of our labor are beginning to emerge, but we believe the best is yet to come. True champions never relent; they tirelessly pursue better outcomes. As a healthcare company, our purpose is to help people worldwide live better and longer lives. Our product range encompasses a wide array of major generic drugs, spanning therapeutic categories such as anti-cancer drugs, CNS medications, and key medicines for conditions like anemia, anxiety disorders, heart failure, hepatitis, HIV/AIDS, and more. Taj Pharmaceuticals is dedicated to improving the human condition by providing effective solutions for common diseases and complex medical challenges. . . #pharma #pharmacy #pharmacist #medicine #healthcare #health #medical #farmacia #research #pharmaindustry #drugs

Chiesi Group celebrates €3bn sales success in 2023 With 31 affiliates globally, Chiesi Group has demonstrated its commitment to delivering tangible benefits for patients, people, and the planet, showcasing the efficacy of its operating model centered around shared value, sustainability, and high ethical standards. "The accelerated evolution experimented by the Chiesi Group in 2023 was consistent with our shared value approach. This means addressing social challenges and business opportunities together, fostering a culture of inclusion, respect, and empowerment among Chiesi Group's 7,000 teammates". The Chiesi Group CARE franchise, catering to specialty care, neonatology, and consumer healthcare, demonstrated consistent growth across regions, with sales up 2% at CER. Notable advancements included the development of a natural surfactant for premature newborns and agreements to address complications of extremely premature birth, underscoring the company's commitment to innovation and patient care. https://lnkd.in/eabQRQZ6 #PublicHealth #Europe #StayInformed #StayEmpowered

🌟 Exciting News in Healthcare! Novo Nordisk Plans to Launch Wegovy in India 🌟 In a significant move, Novo Nordisk, the global pharmaceutical leader, aims to introduce its breakthrough weight-loss drug, Wegovy, to India by 2026. With regulatory approvals and ensuring an adequate supply, Novo Nordisk's India Managing Director, Vikrant Shrotriya, believes this could open up new horizons in healthcare. 🌍 India's Potential: The market opportunity for Wegovy in India is enormous, given the country's high obesity rates, especially among women. This innovative solution could transform the healthcare landscape by offering an alternative to traditional therapies and bariatric surgery. 🚫 Beware of Counterfeits: Shrotriya urges patients not to buy copycat versions of Wegovy, emphasizing their safety concerns. These unlicensed products lack proper transportation and cold chain assurance. 🤝 Commitment to Access: Novo Nordisk recognizes the importance of affordability. While pricing details for Wegovy in India are yet to be confirmed, the company is committed to justifying innovation while ensuring access for patients. 🌟 Wegovy's Efficacy: Wegovy, a weekly injection, is a game-changer in weight loss. Clinical trials have shown it can help users shed about 15% of their body weight, with additional cardiovascular benefits. 🌐 Global Impact: Novo Nordisk first launched Wegovy in the U.S. in 2021 and has expanded into European markets. Demand has been high, and the company aims to be fully prepared to meet India's potential demand Stay tuned for more updates on this exciting development in the world of healthcare. Just follow me. Novo Nordisk's Wegovy could be a game-changer in the fight against obesity in India. Let's watch this space! 👏 #HealthcareInnovation #WegovyInIndia #NovoNordisk #pharmacy

From “Brain Drain” to “Brain Gain”. Greeces’ success story in the GBS sector gains visibility with the deployment of world-class Centres. #EnterpriseGreece #gbs #newbusinessdevelopment

Boehringer to Expand Greek Production Site for New #Medicines German #drugmaker Boehringer Ingelheim is investing €120 million in an upgrade and expansion of its facility in Koropi, #Greece, that will increase the company's capacity to produce existing and new medicines. Main disease areas, Boehringer said, include cardio-renal-metabolic (CRM) diseases, mental #health, and pulmonary fibrosis. According to Boehringer, the expansion will create 110 additional jobs and increase #medicine exports from Greece, particularly of Jardiance, a medication used to treat type 2 #diabetes, chronic (long-term) heart failure and chronic kidney disease, to the US market. Putting innovative production technologies in place to support successful R&D is a key investment driver at Boehringer. In 2022, the company’s global expenditure in human pharma R&D amounted to €4.6 billion. Read more on #CMI online: https://lnkd.in/eivrznTW